Evidence map›Paper›PMID 39494235›Full record

ArticleFrontiers in cardiovascular medicine2024

PD-1/PD-L1 and coronary heart disease: a mendelian randomization study.

Liangjia Zeng, Yinglan Liang, Ruoyun Zhou, Wenting Yang, Kexin Chen, Baixin He, Yuqing Qiu, Linglong Liu, Deyang Zhou, Zhaolin Xiao and 6 more

Abstract read
In one paragraph

Article in Frontiers in cardiovascular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Liangjia ZengThe Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.
Yinglan LiangMedical Exploration and Translation Team, Cardiovascular Medicine and Cardio-Oncology Group, Guangzhou, China.
Ruoyun ZhouDepartment of Clinical Medicine, Clinical Medical School, Guangzhou Medical University, Guangzhou, China.
Wenting YangMedical Exploration and Translation Team, Cardiovascular Medicine and Cardio-Oncology Group, Guangzhou, China.
Kexin ChenDepartment of Clinical Medicine, Clinical Medical School, Guangzhou Medical University, Guangzhou, China.
Baixin HeDepartment of Clinical Medicine, Clinical Medical School, Guangzhou Medical University, Guangzhou, China.
Yuqing QiuDepartment of Clinical Medicine, Clinical Medical School, Guangzhou Medical University, Guangzhou, China.
Linglong LiuMedical Exploration and Translation Team, Cardiovascular Medicine and Cardio-Oncology Group, Guangzhou, China.
Deyang ZhouMedical Exploration and Translation Team, Cardiovascular Medicine and Cardio-Oncology Group, Guangzhou, China.
Zhaolin XiaoDepartment of Clinical Medicine, Clinical Medical School, Guangzhou Medical University, Guangzhou, China.
Haowen LiangDepartment of Clinical Medicine, Clinical Medical School, Guangzhou Medical University, Guangzhou, China.
Binghua ZhangDepartment of Clinical Medicine, Clinical Medical School, Guangzhou Medical University, Guangzhou, China.
Renyu LiMedical Exploration and Translation Team, Cardiovascular Medicine and Cardio-Oncology Group, Guangzhou, China.
Lihong YuSchool of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, China.
Min YiDepartment of Endocrinology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Xiaozhen LinDepartment of Cardiology, Guangzhou Institute of Cardiovascular Disease, Guangdong Key Laboratory of Vascular Diseases, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: It has been found that programmed cell death protein-1 (PD-1) or its ligand PD-L1 may play an important role in the onset and progression of coronary heart disease (CHD). Thus, we conducted this mendelian randomization analysis (MR) to estimate the causal relationship between PD-1/PD-L1 and 5 specific CHDs (chronic ischemic heart disease, acute myocardial infarction, angina pectoris, coronary atherosclerosis, and unstable angina pectoris), complemented by gene set enrichment analysis (GSEA) for further validation. Methods: Publicly available summary-level data were attained from the UK Biobank with genetic instruments obtained from the largest available, nonoverlapping genome-wide association studies (GWAS). Our analysis involved various approaches including inverse variance-weighted meta-analysis, alternative techniques like weighted median, MR-Egger, MR-multipotency residuals and outliers detection (PRESSO), along with multiple sensitivity assessments such as MR-Egger intercept test, Cochran's Q test, and leave-one-out sensitivity analysis to evaluate and exclude any anomalies. Results: Gene expression profile (GSE71226) was obtained from Gene Expression Omnibus (GEO) database for GSEA. IVW analysis showed a causal association between PD-1 and chronic ischemic heart disease (OR, 0.997; 95%CI, 0.995-0.999; Discussion: This study provided evidence of a bidirectional causal relationship between PD-1 and chronic ischemic heart disease and a protective association between chronic ischemic heart disease and PD-L1.

Indexed as

coronary heart disease (CHD)GSEAMendelian randomization (MR)PD-1PD-L1

Identifiers

PMID39494235
PMCPMC11527656

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.